Advanced Search

    Technical Analysis for AKRO - Akero Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 38.26 1.22% 0.46
    AKRO closed up 1.22 percent on Friday, March 31, 2023, on 1.72 times normal volume.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Flat
    Historical AKRO trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Bearish Engulfing Bearish 1.22%
    Multiple of Ten Bearish Other 1.22%
    Outside Day Range Expansion 1.22%
    Wide Bands Range Expansion 1.22%
    1,2,3 Retracement Bearish Bearish Swing Setup -5.06%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.06%
    Older End-of-Day Signals for AKRO ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 1% 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Possible NR7 1 day ago
    Possible Inside Day 1 day ago
    Rose Above 10 DMA 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AKRO Chart by TradingView
    Basic chart:

    Profile

    Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Alcohol Clinical Trial Steatohepatitis Hepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease

    Is AKRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 29 Akero plans to begin Phase 3 trial of NASH treatment in H2 after successful FDA meet
    Mar 29 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
    Mar 22 Top 1% Biotech 89bio Scores 39% Gain As Battle In Liver Disease Heats Up
    Mar 17 Akero Therapeutics GAAP EPS of -$0.49 beats by $0.31
    Mar 17 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
    Feb 8 Akero Therapeutics: NASH Differentiator Attractive, Awaiting Additional Price Catalysts
    Jan 27 Akero upgraded at Morgan Stanley on NASH prospects
    Jan 10 Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
    Jan 4 Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
    Dec 22 Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
    See more AKRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 54.88
    52 Week Low 7.52
    Average Volume 561,471
    200-Day Moving Average 32.78
    50-Day Moving Average 44.09
    20-Day Moving Average 40.78
    10-Day Moving Average 38.43
    Average True Range 2.30
    RSI 41.18
    ADX 32.24
    +DI 11.40
    -DI 26.92
    Chandelier Exit (Long, 3 ATRs) 41.49
    Chandelier Exit (Short, 3 ATRs) 42.27
    Upper Bollinger Bands 47.15
    Lower Bollinger Band 34.41
    Percent B (%b) 0.3
    BandWidth 31.23
    MACD Line -1.77
    MACD Signal Line -1.76
    MACD Histogram -0.0153
    Fundamentals Value
    Market Cap 1.33 Billion
    Num Shares 34.7 Million
    EPS -91.75
    Price-to-Earnings (P/E) Ratio -0.42
    Price-to-Sales 0.00
    Price-to-Book 3.39
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 40.69
    Resistance 3 (R3) 40.66 39.83 40.29
    Resistance 2 (R2) 39.83 39.21 39.84 40.15
    Resistance 1 (R1) 39.04 38.83 39.44 39.07 40.01
    Pivot Point 38.21 38.21 38.40 38.22 38.21
    Support 1 (S1) 37.42 37.59 37.82 37.45 36.51
    Support 2 (S2) 36.59 37.21 36.60 36.37
    Support 3 (S3) 35.80 36.59 36.24
    Support 4 (S4) 35.83